{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:29:25Z","timestamp":1783434565793,"version":"3.54.6"},"reference-count":25,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Co-prescribing medications that can interact with direct-acting oral anticoagulants (DOACs) may decrease their safety and efficacy. The aim of this study was to examine the co-prescribing of such medications with DOACs using the Australian national general practice dataset, MedicineInsight, over a five-year period. Methods: We performed five sequential cross-sectional analyses in patients with atrial fibrillation (AF) and a recorded DOAC prescription. Patients were defined as having a drug interaction if they had a recorded prescription of an interacting medication while they had had a recorded prescription of DOAC in the previous six months. The sample size for the cross-sectional analyses ranged from 5333 in 2014 to 19,196 in 2018. Results: The proportion of patients who had potential drug interactions with a DOAC decreased from 45.9% (95% confidence interval (CI) 44.6%\u201347.4%) in 2014 to 39.9% (95% CI 39.2%\u201340.6%) in 2018, p for trend &lt; 0.001. During this period, the most frequent interacting class of medication recorded as having been prescribed with DOACs was selective serotonin\/serotonin and norepinephrine reuptake inhibitor (SSRI\/SNRI) antidepressants, followed by non-steroidal anti-inflammatory drugs (NSAIDs), calcium channel blockers (CCBs) and amiodarone. Conclusions: Overall, potential drug interactions with DOACs have decreased slightly over the last five years; however, the rate of possible interaction with SSRIs\/SNRIs has remained relatively unchanged and warrants awareness-raising amongst prescribers.<\/jats:p>","DOI":"10.3390\/jcm9113568","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T19:38:41Z","timestamp":1604605121000},"page":"3568","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Five-Year Trends in Potential Drug Interactions with Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation: An Australian-Wide Study"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3028-6949","authenticated-orcid":false,"given":"Woldesellassie M.","family":"Bezabhe","sequence":"first","affiliation":[{"name":"School of Pharmacy and Pharmacology, University of Tasmania, Private Bag 26, Hobart, Tasmania 7001, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3974-3437","authenticated-orcid":false,"given":"Luke R.","family":"Bereznicki","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmacology, University of Tasmania, Private Bag 26, Hobart, Tasmania 7001, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5751-0488","authenticated-orcid":false,"given":"Jan","family":"Radford","sequence":"additional","affiliation":[{"name":"Launceston Clinical School, Tasmanian School of Medicine, University of Tasmania, Launceston 7250, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara C.","family":"Wimmer","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmacology, University of Tasmania, Private Bag 26, Hobart, Tasmania 7001, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9131-7465","authenticated-orcid":false,"given":"Mohammed S.","family":"Salahudeen","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmacology, University of Tasmania, Private Bag 26, Hobart, Tasmania 7001, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8170-8339","authenticated-orcid":false,"given":"Ivan","family":"Bindoff","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmacology, University of Tasmania, Private Bag 26, Hobart, Tasmania 7001, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Garrahy","sequence":"additional","affiliation":[{"name":"Launceston Clinical School, Tasmanian School of Medicine, University of Tasmania, Launceston 7250, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Peterson","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmacology, University of Tasmania, Private Bag 26, Hobart, Tasmania 7001, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e13070","DOI":"10.1111\/ijcp.13070","article-title":"Epidemiology of atrial fibrillation","volume":"72","author":"Zulkifly","year":"2018","journal-title":"Int. J. Clin. Pr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"k1453","DOI":"10.1136\/bmj.k1453","article-title":"Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: Cohort study based on longitudinal data from the Framingham Heart Study","volume":"361","author":"Staerk","year":"2018","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart Disease and Stroke Statistics\u20142019 Update: A Report From the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.amjcard.2017.06.055","article-title":"Changes in Oral Anticoagulant Prescribing for Stroke Prevention in Patients With Atrial Fibrillation","volume":"120","author":"Alamneh","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_5","unstructured":"Drug Utilisation Sub-Committee (DUSC) (2016). Novel Oral Anticoagulant: Predicted vs. Actual Analysis. Public Release Document: National Prescribing Service."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","unstructured":"(2020, September 14). MIMS ONLINE [Database on the Internet]. Available online: https:\/\/www.mimsonline.com.au\/Search\/DrugAlertSearch.aspx?ModuleName=Drug%20Interactions&search."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jacc.2018.04.063","article-title":"Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation","volume":"72","author":"Kent","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"i2868","DOI":"10.1136\/bmj.i2868","article-title":"Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: Post hoc analysis of the ARISTOTLE trial","volume":"353","author":"Focks","year":"2016","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Hear. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: Pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jacc.2019.12.068","article-title":"Select Drug-Drug Interactions With Direct Oral Anticoagulants","volume":"75","author":"Wiggins","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3389\/fneur.2018.01067","article-title":"Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs","volume":"9","author":"Galgani","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.amjmed.2018.10.008","article-title":"Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation","volume":"132","author":"Douros","year":"2018","journal-title":"Am. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/bcp.14227","article-title":"Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case\u2013control study","volume":"86","author":"Zhang","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bezabhe, W.M., Kitsos, A., Saunder, T., Peterson, G.M., Bereznicki, L.R., Wimmer, B.C., Jose, M., and Radford, J. (2020). Medication Prescribing Quality in Australian Primary Care Patients with Chronic Kidney Disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9030783"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-020-01862-1","article-title":"Quality use of medicines in patients with chronic kidney disease","volume":"21","author":"Castelino","year":"2020","journal-title":"BMC Nephrol."},{"key":"ref_19","unstructured":"(2020). MedicineInsight Data Book and Data Dictionary, NPS MedicineWise."},{"key":"ref_20","unstructured":"PSA R, and ASCEPT (2020). Australain Medicines Handbook, Pty Ltd."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.hlc.2018.06.1043","article-title":"National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018","volume":"27","author":"Brieger","year":"2018","journal-title":"Hear. Lung Circ."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/2042098617719815","article-title":"Potential drug\u2013drug interactions with direct oral anticoagulants in elderly hospitalized patients","volume":"8","author":"Forbes","year":"2017","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.amjcard.2014.05.037","article-title":"Effect of Selective Serotonin Reuptake Inhibitors on Bleeding Risk in Patients With Atrial Fibrillation Taking Warfarin","volume":"114","author":"Quinn","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association Between Use of Non\u2013Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"key":"ref_25","first-page":"1741","article-title":"Data Resource Profile: MedicineInsight, an Australian national primary health care database","volume":"48","author":"Busingye","year":"2019","journal-title":"Int. J. Epidemiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3568\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:29:52Z","timestamp":1760178592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/11\/3568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["jcm9113568"],"URL":"https:\/\/doi.org\/10.3390\/jcm9113568","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]}}}